Skip to main content
. 2014 Feb 12;35(6):1267–1275. doi: 10.1093/carcin/bgu038

Table II.

Comparisons of demographic characteristics of patients according to HPV16/18 status (published datasets only)

Characteristic Asia, Europe and South/Central America North America
Total (N = 2500) HPV16/18 positive (N = 233, 9.3%) HPV16/18 negative (N = 2267, 90.7%) P valuea Total (N = 663) HPV16/18 positive (N = 23, 3.5%) HPV16/18 negative (N = 640, 96.5%) P valuea
Gender 0.157 0.632
    Male 1749 (71.92) 154 (66.96) 1595 (72.43) 349 (52.64) 10 (43.48) 339 (52.97)
    Female 683 (28.08) 76 (33.04) 607 (27.57) 314 (47.36) 13 (56.52) 301 (47.03)
Age (years) 0.529 0.557
    ≤66 1212 (51.33) 92 (42.4) 1120 (52.24) 315 (47.51) 10 (43.48) 305 (47.66)
    >66 1149 (48.67) 125 (57.6) 1024 (47.76) 348 (52.49) 13 (56.52) 335 (52.34)
Race 0.059 0.102
    White 1083 (43.32) 27 (11.59) 1056 (46.58) 239 (88.52) 13 (72.22) 226 (89.68)
    Othersb 1417 (56.68) 206 (88.41) 1211 (53.42) 31 (11.48) 5 (27.78) 26 (10.32)
Smoking history 0.762 0.256
    Never smoked 602 (24.06) 67 (28.93) 534 (23.56) 104 (15.69) 3 (13.04) 101 (15.78)
    Ever smoked 1898 (75.94) 166 (71.07) 1733 (76.44) 559 (84.31) 20 (86.96) 539 (84.22)
Histology 0.536 0.345
    SCC 953 (38.12) 107 (45.92) 846 (37.32) 239 (36.43) 5 (22.73) 234 (36.91)
    Othersc 1547 (61.88) 126 (54.08) 1421 (62.68) 417 (63.57) 17 (77.27) 400 (63.09)
Stage 0.614 0.099
    0/Id 1240 (49.60) 108 (46.52) 1132 (49.92) 422 (63.63) 15 (65.65) 407 (63.59)
    II 460 (18.41) 36 (15.41) 424 (18.72) 106 (16.01) 1 (5.59) 105 (16.39)
    III 479 (19.14) 43 (18.37) 436 (19.22) 109 (16.43) 3 (13.91) 106 (16.53)
    IV 321 (12.84) 46 (19.70) 275 (12.14) 26 (3.93) 4 (16.52) 22 (3.48)

Data are presented as number of patients (%).

a P value was calculated by a logistic regression model with study as a random effect.

bOthers include Black, Hispanic, Asian and race not specified.

cOthers include adenocarcinoma and histology not specified.

dIncludes four cases with stage 0 (in situ).